The Role of MMP2 (-1306C>T) and TIMP2 (-418 G>C) Promoter Variants in Age-related Macular Degeneration

REFERENCES

• Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257–293
   PubMed Web of Science ®Google Scholar
• Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron 2012;75:26–39
   PubMed Web of Science ®Google Scholar
• Hageman GS, Mullins RF. Molecular composition of drusen as related to substructural phenotype. Mol Vis 1999;5:28
   PubMed Web of Science ®Google Scholar
• Johnson LV, Ozaki S, Staples MK, et al. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res 2000;70:441–449
   PubMed Web of Science ®Google Scholar
• Nagai N, Klimava A, Lee WH, et al. CTGF is increased in basal deposits and regulates matrix production through the ERK (p42/p44mapk) MAPK and the p38 MAPK signaling pathways. Invest Ophthalmol Vis Sci 2009;50:1903–1910
   PubMed Web of Science ®Google Scholar
• Booij JC, Baas DC, Beisekeeva J, et al. The dynamic nature of Bruch’s membrane. Prog Retin Eye Res 2010;29:1–18
   PubMed Web of Science ®Google Scholar
• Starita C, Hussain AA, Pagliarini S, Marshall J. Hydrodynamics of ageing Bruch’s membrane: implications for macular disease. Exp Eye Res. 1996;62:565–572
   PubMed Web of Science ®Google Scholar
• Strauss O. The retinal pigment epithelium in visual function. Physiol Rev 2005;85:845–881
   PubMed Web of Science ®Google Scholar
• McLeod DS, Taomoto M, Otsuji T, et al. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 2002;43:1986–1993
   PubMed Web of Science ®Google Scholar
• Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000;14:2123–2133
   PubMed Web of Science ®Google Scholar
• Sethi CS, Bailey TA, Luthert PJ, Chong NH. Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol 2000;84:654–666
   PubMed Web of Science ®Google Scholar
• Steen B, Sejersen S, Berglin L, et al. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1998;39:2194–2200
   PubMed Web of Science ®Google Scholar
• Plantner JJ, Jiang C, Smine A. Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. Exp Eye Res 1998;67:637–645
   PubMed Web of Science ®Google Scholar
• Weber BH, Vogt G, Pruett RC, et al. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby’s fundus dystrophy. Nat Genet 1994;8:352–356
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yu C, Miao X, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 2004;25:399–404
   PubMed Web of Science ®Google Scholar
• Davis MD, Gangnon RE, Lee LY, et al; Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005;123:1484–1498
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33:S62–S69
   PubMed Web of Science ®Google Scholar
• Marin-Castaño ME, Striker GE, Alcazar O, et al. Repetitive nonlethal oxidant injury to retinal pigment epithelium decreased extracellular matrix turnover in vitro and induced sub-RPE deposits in vivo. Invest Ophthalmol Vis Sci 2006;47:4098–4112
   PubMed Web of Science ®Google Scholar
• Peten EP, Garcia-Perez A, Terada Y, et al. Age-related changes in alpha 1- and alpha 2-chain type IV collagen mRNAs in adult mouse glomeruli: competitive PCR. Am J Physiol 1992;263:F951–F957
   Google Scholar
• Evans JR. Risk factors for age-related macular degeneration. Prog Retin Eye Res 2001;20:227–253
   PubMed Web of Science ®Google Scholar
• Pons M, Cousins SW, Alcazar O, et al. Angiotensin II-induced MMP-2 activity and MMP-14 and basigin protein expression are mediated via the angiotensin II receptor type 1-mitogen-activated protein kinase 1 pathway in retinal pigment epithelium: implications for age-related macular degeneration. Am J Pathol 2011;178:2665–2681
   PubMed Web of Science ®Google Scholar
• Chong NH, Keonin J, Luthert PJ, et al. Decreased thickness and integrity of the macular elastic layer of Bruch’s membrane correspond to the distribution of lesions associated with age-related macular degeneration. Am J Pathol 2005;166:241–251
   PubMed Web of Science ®Google Scholar
• Nackman GB, Karkowski FJ, Halpern VJ, et al. Elastin degradation products induce adventitial angiogenesis in the Anidjar/Dobrin rat aneurysm model. Surgery 1997;122:39–44
   PubMed Web of Science ®Google Scholar
• Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007;211:19–26
   PubMed Web of Science ®Google Scholar
• Guo L, Hussain AA, Limb GA, Marshall J. Age-dependent variation in metalloproteinase activity of isolated human Bruch’s membrane and choroid. Invest Ophthalmol Vis Sci 1999;40:2676–2682
   PubMed Web of Science ®Google Scholar
• Hussain AA, Lee Y, Zhang JJ, Marshall J. Disturbed matrix metalloproteinase activity of Bruch’s membrane in age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52:4459–4466
   PubMed Web of Science ®Google Scholar
• Ahir A, Guo L, Hussain AA, Marshall J. Expression of metalloproteinases from human retinal pigment epithelial cells and their effects on the hydraulic conductivity of Bruch’s membrane. Invest Ophthalmol Vis Sci 2002;43:458–465
   PubMed Web of Science ®Google Scholar
• Chau KY, Sivaprasad S, Patel N, et al. Plasma levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) in age-related macular degeneration. Eye (Lond) 2008;22:855–859
   PubMed Web of Science ®Google Scholar
• Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999;878:236–270
   PubMed Web of Science ®Google Scholar